分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展

据GLOBOCAN 2018估计,肺癌、乳腺癌、结直肠癌、胃癌和肝癌五种癌症占2018年全球新发恶性肿瘤病例的43%左右。越来越多的研究表明,分化拮抗非蛋白质编码RNA(DANCR)在人类多种癌症中表达异常,其异常表达使癌细胞增殖和侵袭,进而促进肿瘤进展。同时,DANCR的表达水平与肿瘤的组织学分级以及患者的预后显著相关,因此将DANCR做为多种癌症的潜在生物标志物。本文通过对长链非编码RNA(lncRNA)DANCR在肺癌、乳腺癌、结直肠癌、肝癌和胃癌等常见恶性肿瘤中的研究进展做一系统综述,以阐释lncRNA DANCR在恶性肿瘤中的分子机制和临床意义。

Progress in differentiation of non-protein-encoding RNA(DANCR)in common malignant tumors

According to GLOBOCAN 2018,lung cancer,breast cancer,colorectal cancer,gastric cancer and liver cancer account for about 43%of new global malignant tumors in 2018.A growing number of studies have shown that differentially antagonizing non-protein-encoding RNA(lncRNA-DANCR)is abnormally expressed in a variety of human cancers,and its aberrant expression promotes tumor progression by improving cancer cell proliferation and invasion.At the same time,the expression level of DANCR is significantly correlated with the histological grade of tumor and the prognosis of patient,making DANCR as a potential biomarker for a variety of cancers.This paper systematically reviews the research progress of lncRNA DANCR in common malignant tumors such as lung cancer,breast cancer,colorectal cancer,gastric cancer and liver cancer,in order to explain the molecular mechanisms and clinical significance of lncRNA DANCR in malignant tumors.